Our aim is to have a continuous dialogue with our investor community to ensure that they understand the great work we are doing as a company as well as any challenges we are facing. We seek to balance the demands of running an innovative science-led pharmaceutical and biotechnology company with those of the markets. Thanks to our early investments in research & development and manufacturing facilities, we are witnessing strong growth momentum across businesses and markets.
For redressal of any grievances, the shareholders/investors may contact the following: